ZIVO Bioscience (ZIVO) Stock Price, News & Analysis

Company Overview

ZIVO Bioscience is a clinical-stage biotechnology company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets. The company applies synthetic biology, microbiology and fermentation technologies to engineer proprietary bacterial strains that produce targeted lactic acid and antimicrobial compounds. Its pipeline includes ZB-01, an orally administered therapy for recurrent Clostridioides difficile infections in humans, and ZB-02, a feed-additive candidate aimed at reducing Salmonella colonization in poultry.

Founded in 2016 and headquartered in Carlsbad, California, ZIVO Bioscience leverages exclusive licensing agreements with academic institutions to advance its lead programs through preclinical and early clinical development. The company’s animal health platform is designed to offer an antibiotic‐free approach to controlling foodborne pathogens, while its human health efforts target high-unmet-need gastrointestinal diseases where current therapies fall short or carry significant safety risks.

ZIVO’s proprietary fermentation processes are scalable and designed to meet regulatory standards for both veterinary and human therapeutics. The company collaborates with contract development and manufacturing organizations (CDMOs) to produce its live bacterial formulations under Good Manufacturing Practices (GMP). These partnerships aim to accelerate the transition of ZIVO’s pipeline assets from research to first-in-human trials and commercial supply.

Under the leadership of CEO Jon Bany, ZIVO Bioscience continues to build a multidisciplinary team of experts in microbiology, immunology and process development. The company’s strategic focus on dual animal and human health applications reflects a growing industry emphasis on microbiome-based solutions that improve public health outcomes while addressing regulatory pressures to reduce antibiotic use in agriculture.

Key Stats

• Today's Range: $13.01 to $13.01
• 50-Day Range: $9.97 to $19.01
• 52-Week Range: $9.97 to $22.15
• Volume: 661 shs
• Average Volume: 1,077 shs
• Market Capitalization: $49.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZIVO Bioscience Stock Analysis - MarketRank™

ZIVO Bioscience scored higher than 3% of companies evaluated by MarketBeat, and ranked 944th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ZIVO Bioscience.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ZIVO Bioscience is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ZIVO Bioscience is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.67% of the float of ZIVO Bioscience has been sold short.

Short Interest Ratio / Days to Cover

ZIVO Bioscience has a short interest ratio ("days to cover") of 24.3, which indicates bearish sentiment.

Change versus previous month

Short interest in ZIVO Bioscience has recently decreased by 1.82%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ZIVO Bioscience does not currently pay a dividend.

Dividend Growth

ZIVO Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.67% of the float of ZIVO Bioscience has been sold short.

Short Interest Ratio / Days to Cover

ZIVO Bioscience has a short interest ratio ("days to cover") of 24.3, which indicates bearish sentiment.

Change versus previous month

Short interest in ZIVO Bioscience has recently decreased by 1.82%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added ZIVO Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ZIVO Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

48.90% of the stock of ZIVO Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.83% of the stock of ZIVO Bioscience is held by institutions.

ZIVO Stock Analysis - Frequently Asked Questions

How have ZIVO shares performed this year?

ZIVO Bioscience's stock was trading at $21.50 at the start of the year. Since then, ZIVO stock has decreased by 39.5% and is now trading at $13.01.

How were ZIVO Bioscience's earnings last quarter?

ZIVO Bioscience, Inc. (NASDAQ:ZIVO) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.06) earnings per share for the quarter. The biotechnology company had revenue of $0.02 million for the quarter.

When did ZIVO Bioscience's stock split?

Shares of ZIVO Bioscience reverse split before market open on Friday, October 27th 2023.The 1-6 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of ZIVO Bioscience?

Shares of ZIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ZIVO Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIVO Bioscience investors own include Canopy Growth (CGC), Meta Platforms (META), OPKO Health (OPK), Johnson & Johnson (JNJ), ACADIA Pharmaceuticals (ACAD), ARAVIVE (ARAV) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 9/20/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZIVO
• Previous Symbol: OTCMKTS:HEPI
• CIK: 1101026
• Web: www.zivobioscience.com
• Phone: (248) 452-9866
• Fax: N/A
• Employees: 10
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): ($2.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.78 million
• Net Margins: N/A
• Pretax Margin: -17,113.75%
• Return on Equity: N/A
• Return on Assets: -2,240.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: $15.85 thousand
• Price / Sales: 3,133.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.81) per share
• Price / Book: -16.06

Miscellaneous

• Outstanding Shares: 3,817,000
• Free Float: 2,911,000
• Market Cap: $49.66 million
• Optionable: Not Optionable
• Beta: N/A